Matthew P. Frosch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew P. Frosch has a total of 362 co-authors. Here are the top co-authors by number of shared publications:
- Maria Martinez-Lage
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
16 shared publications - Mario L. Suva
Department of Pathology and Krantz Family Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
16 shared publications - Aarushi Jain
Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
15 shared publications - Albert Eusik Kim
Department of Neurology, Massachusetts General Hospital and Harvard Medical School , 55 Fruit Street, Boston, MA 02114
15 shared publications - Alexander Kaplan
Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
15 shared publications - Andrew W. Navia
Broad Institute of MIT and Harvard
15 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (5) , e200419
Neuropathologic Features of Adult-Onset Progressive Leukodystrophy Due to KARS Pathogenic Variants
ObjectivesTo report the histopathologic features seen in congenital deafness and adult-onset leukoencephalopathy (DEAPLE) caused by biallelic pathogenic variants in KARS and expand on neuroradiolog...
- 1 October 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (5) , e200419
Open AccessNeuropathologic Features of Adult-Onset Progressive Leukodystrophy Due to KARS Pathogenic Variants
ObjectivesTo report the histopathologic features seen in congenital deafness and adult-onset leukoencephalopathy (DEAPLE) caused by biallelic pathogenic variants in KARS and expand on neuroradiolog...
- Open Access
- 17 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0355740
A public generalizable AI tool for automated segmentation of coronal brain tissue slabs for 3D neuropathology
Advances in image registration and machine learning have recently enabled volumetric analysis of postmortem brain tissue from conventional photographs of coronal slabs, which are routinely collected in brain banks and neuropathology laboratories around the world. One caveat of this methodology is the requirement of segmentation of the tissue from the background and out-of-slice tissue in photographs, which currently requires laborious manual intervention. Manual delineation is a bottleneck in this process and poses challenges in scalability, and resources, restricting adoption of these methods. In this article, we present a deep learning model to automate this process. The automatic segmentation tool relies on a U-Net architecture that was trained with a combination of 1,414 manually segmented images of both fixed and fresh tissue, from specimens with varying diagnoses, photographed at two different sites. Automated model predictions on a subset of photographs not seen in training were analyzed to estimate performance compared to manual labels, including both inter- and intra-rater variability. Our model achieved a median Dice score over 0.98, mean surface distance under 0.4 mm, and 95% Hausdorff distance under 1.60 mm, which approaches inter-/intra-rater levels. Our tool is publicly available at surfer.nmr.mgh.harvard.edu/fswiki/PhotoTools and training data is available at https://zenodo.org/records/20647553 .
- 17 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0355740
Open AccessA public generalizable AI tool for automated segmentation of coronal brain tissue slabs for 3D neuropathology
Advances in image registration and machine learning have recently enabled volumetric analysis of postmortem brain tissue from conventional photographs of coronal slabs, which are routinely collected in brain banks and neuropathology laboratories around the world. One caveat of this methodology is the requirement of segmentation of the tissue from the background and out-of-slice tissue in photographs, which currently requires laborious manual intervention. Manual delineation is a bottleneck in this process and poses challenges in scalability, and resources, restricting adoption of these methods. In this article, we present a deep learning model to automate this process. The automatic segmentation tool relies on a U-Net architecture that was trained with a combination of 1,414 manually segmented images of both fixed and fresh tissue, from specimens with varying diagnoses, photographed at two different sites. Automated model predictions on a subset of photographs not seen in training were analyzed to estimate performance compared to manual labels, including both inter- and intra-rater variability. Our model achieved a median Dice score over 0.98, mean surface distance under 0.4 mm, and 95% Hausdorff distance under 1.60 mm, which approaches inter-/intra-rater levels. Our tool is publicly available at surfer.nmr.mgh.harvard.edu/fswiki/PhotoTools and training data is available at https://zenodo.org/records/20647553 .
- Open Access
Assessing AI and Neurologist Diagnostic Reasoning Against Neuropathological Ground Truth
BACKGROUND Accurate differential diagnosis of complex neurological disorders remains challenging due to overlapping clinical features and heterogeneous disease presentations. Although large language models (LLMs) show promise in clinical reasoning, prior studies benchmark performance against clinician consensus rather than biological ground truth. A neuropathologically confirmed benchmark dataset for evaluating diagnostic AI in neurology is currently lacking. METHODS We introduce NeuroBench, a curated benchmark of complex neurological cases with neuropathologically confirmed gold-standard diagnoses, and DIAGNO, a confidence-aware LLM-based system for neurological diagnosis. NeuroBench comprises 203 retrospective case summaries from the Massachusetts General Hospital Brain Cutting Conference with corresponding autopsy-confirmed diagnoses. DIAGNO generated top-3 differential diagnoses, employing retrieval-augmented generation (RAG) for lower-confidence cases. Performance was assessed by three independent blinded adjudicators who evaluated both DIAGNO and neurologists against neuropathological ground truth. RESULTS NeuroBench encompassed 79 unique neuropathological diagnoses, spanning conditions including cerebrovascular disease, brain tumors, neurological infections, and various neurodegenerative and inflammatory disorders. DIAGNO matched or outperformed neurologists in top-3 accuracy (0.67 versus 0.63) and taxonomy-level accuracy (0.74 versus 0.66). In cases of disagreement, DIAGNO was more often correct than neurologists (29 versus 19 cases). Diagnostic concordance between DIAGNO and neurologists was high (90% agreement in top-3 predictions), even when both were incorrect, suggesting strong alignment in diagnostic reasoning. On NeuroBench, DIAGNO also outperformed GPT-4o baseline and DeepSeek R1 across all top-k accuracy metrics. In a real-world evaluation on eight complex cases with differentials from Mass General Brigham, neurologists rated DIAGNO's reasoning favorably (mean 4.03/5) across multiple dimensions of clinical utility and safety. CONCLUSIONS NeuroBench establishes neuropathological confirmation as the appropriate standard for evaluating diagnostic AI in neurology, moving beyond clinician-referenced benchmarking to define the ceiling of diagnostic accuracy. Evaluated against this standard, DIAGNO achieved expert-level diagnostic performance and received favorable clinician ratings in real-world applications, supporting its potential as a clinical decision-support tool in neurology.
Open AccessAssessing AI and Neurologist Diagnostic Reasoning Against Neuropathological Ground Truth
BACKGROUND Accurate differential diagnosis of complex neurological disorders remains challenging due to overlapping clinical features and heterogeneous disease presentations. Although large language models (LLMs) show promise in clinical reasoning, prior studies benchmark performance against clinician consensus rather than biological ground truth. A neuropathologically confirmed benchmark dataset for evaluating diagnostic AI in neurology is currently lacking. METHODS We introduce NeuroBench, a curated benchmark of complex neurological cases with neuropathologically confirmed gold-standard diagnoses, and DIAGNO, a confidence-aware LLM-based system for neurological diagnosis. NeuroBench comprises 203 retrospective case summaries from the Massachusetts General Hospital Brain Cutting Conference with corresponding autopsy-confirmed diagnoses. DIAGNO generated top-3 differential diagnoses, employing retrieval-augmented generation (RAG) for lower-confidence cases. Performance was assessed by three independent blinded adjudicators who evaluated both DIAGNO and neurologists against neuropathological ground truth. RESULTS NeuroBench encompassed 79 unique neuropathological diagnoses, spanning conditions including cerebrovascular disease, brain tumors, neurological infections, and various neurodegenerative and inflammatory disorders. DIAGNO matched or outperformed neurologists in top-3 accuracy (0.67 versus 0.63) and taxonomy-level accuracy (0.74 versus 0.66). In cases of disagreement, DIAGNO was more often correct than neurologists (29 versus 19 cases). Diagnostic concordance between DIAGNO and neurologists was high (90% agreement in top-3 predictions), even when both were incorrect, suggesting strong alignment in diagnostic reasoning. On NeuroBench, DIAGNO also outperformed GPT-4o baseline and DeepSeek R1 across all top-k accuracy metrics. In a real-world evaluation on eight complex cases with differentials from Mass General Brigham, neurologists rated DIAGNO's reasoning favorably (mean 4.03/5) across multiple dimensions of clinical utility and safety. CONCLUSIONS NeuroBench establishes neuropathological confirmation as the appropriate standard for evaluating diagnostic AI in neurology, moving beyond clinician-referenced benchmarking to define the ceiling of diagnostic accuracy. Evaluated against this standard, DIAGNO achieved expert-level diagnostic performance and received favorable clinician ratings in real-world applications, supporting its potential as a clinical decision-support tool in neurology.
- Open Access
- 13 May 2026
- Published by Wiley in Hippocampus
- Vol. 36 (3) , e70101
Quantitative and Morphometric Measures in the Human Hippocampal Tail Using Ex Vivo Imaging Validated With Histology
The human hippocampal tail is the posterior‐most portion of the hippocampus and has been implicated in brain disorders, such as depression, panic disorder, and epilepsy. The tail's clinical relevance and volumetric variability exhibit a need for improved characterization with high‐resolution imaging and histology at baseline. MRI provides three‐dimensional context without missing slices and histology validates with architecture; combining these methods provides an optimal approach. Twenty control brain hemispheres were evaluated, including 10 males and 10 females. We scanned the hemispheres using ex vivo MRI at 120 μm isotropic resolution. The tissue was then processed and histologically stained. We manually labeled the hippocampal tail in high‐resolution MRI, using six distinct coronal levels of the tail as guideposts, validating histologically. The volume and length of the tails were calculated using 3D MRI reconstructions; the median tail volume (median ± interquartile range) of our sample set was 715.6 ± 227.5 mm 3 . These data contribute a validated hippocampal tail volume. We calculated and quantified the medial flexure of the tail and compared sex as a biological variable. Male tail samples exhibited significantly larger angles than female samples (Mann–Whitney U test, p = 0.01). Our findings enable precise hippocampal tail delineation and may facilitate future research on function and mental health disorders.
- 13 May 2026
- Published by Wiley in Hippocampus
- Vol. 36 (3) , e70101
Open AccessQuantitative and Morphometric Measures in the Human Hippocampal Tail Using Ex Vivo Imaging Validated With Histology
The human hippocampal tail is the posterior‐most portion of the hippocampus and has been implicated in brain disorders, such as depression, panic disorder, and epilepsy. The tail's clinical relevance and volumetric variability exhibit a need for improved characterization with high‐resolution imaging and histology at baseline. MRI provides three‐dimensional context without missing slices and histology validates with architecture; combining these methods provides an optimal approach. Twenty control brain hemispheres were evaluated, including 10 males and 10 females. We scanned the hemispheres using ex vivo MRI at 120 μm isotropic resolution. The tissue was then processed and histologically stained. We manually labeled the hippocampal tail in high‐resolution MRI, using six distinct coronal levels of the tail as guideposts, validating histologically. The volume and length of the tails were calculated using 3D MRI reconstructions; the median tail volume (median ± interquartile range) of our sample set was 715.6 ± 227.5 mm 3 . These data contribute a validated hippocampal tail volume. We calculated and quantified the medial flexure of the tail and compared sex as a biological variable. Male tail samples exhibited significantly larger angles than female samples (Mann–Whitney U test, p = 0.01). Our findings enable precise hippocampal tail delineation and may facilitate future research on function and mental health disorders.
- 14 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6701) , eadh9979
Integrated platform for multiscale molecular imaging and phenotyping of the human brain
Understanding cellular architectures and their connectivity is essential for interrogating system function and dysfunction. However, we lack technologies for mapping the multiscale details of individual cells and their connectivity in the human organ–scale system. We developed a platform that simultaneously extracts spatial, molecular, morphological, and connectivity information of individual cells from the same human brain. The platform includes three core elements: a vibrating microtome for ultraprecision slicing of large-scale tissues without losing cellular connectivity (MEGAtome), a polymer hydrogel–based tissue processing technology for multiplexed multiscale imaging of human organ–scale tissues (mELAST), and a computational pipeline for reconstructing three-dimensional connectivity across multiple brain slabs (UNSLICE). We applied this platform for analyzing human Alzheimer’s disease pathology at multiple scales and demonstrating scalable neural connectivity mapping in the human brain.
- 14 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6701) , eadh9979
Integrated platform for multiscale molecular imaging and phenotyping of the human brain
Understanding cellular architectures and their connectivity is essential for interrogating system function and dysfunction. However, we lack technologies for mapping the multiscale details of individual cells and their connectivity in the human organ–scale system. We developed a platform that simultaneously extracts spatial, molecular, morphological, and connectivity information of individual cells from the same human brain. The platform includes three core elements: a vibrating microtome for ultraprecision slicing of large-scale tissues without losing cellular connectivity (MEGAtome), a polymer hydrogel–based tissue processing technology for multiplexed multiscale imaging of human organ–scale tissues (mELAST), and a computational pipeline for reconstructing three-dimensional connectivity across multiple brain slabs (UNSLICE). We applied this platform for analyzing human Alzheimer’s disease pathology at multiple scales and demonstrating scalable neural connectivity mapping in the human brain.
- 23 January 2024
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 11 (4) , 411-423
Gerstmann‐Sträussler‐Scheinker Disease Presenting as Late‐Onset Slowly Progressive Spinocerebellar Ataxia, and Comparative Case Series with Neuropathology
Background: Genetic prion diseases, including Gerstmann‐Sträussler‐Scheinker disease (GSS), are extremely rare, fatal neurodegenerative disorders, often associated with progressive ataxia and cognitive/neuropsychiatric symptoms. GSS typically presents as a rapidly progressive cerebellar ataxia, associated with cognitive decline. Late‐onset cases are rare.Objective: To compare a novel GSS phenotype with six other cases and present pathological findings from a single case.Methods: Case series of seven GSS patients, one proceeding to autopsy.Results: Case 1 developed slowly progressive gait difficulties at age 71, mimicking a spinocerebellar ataxia, with a family history of balance problems in old age. Genome sequencing revealed a heterozygous c.392G > A (p.G131E) pathogenic variant and a c.395A > G resulting in p.129 M/V polymorphism in the PRNP gene. Probability analyses considering family history, phenotype, and a similar previously reported point mutation (p.G131V) suggest p.G131E as a new pathogenic variant. Clinical features and imaging of this case are compared with those six additional cases harboring p.P102L mutations. Autopsy findings of a case are described and were consistent with the prion pathology of GSS.Conclusions: We describe a patient with GSS with a novel p.G131E mutation in the PRNP gene, presenting with a late‐onset, slowly progressive phenotype, mimicking a spinocerebellar ataxia, and six additional cases with the typical P102L mutation.
- 23 January 2024
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 11 (4) , 411-423
Gerstmann‐Sträussler‐Scheinker Disease Presenting as Late‐Onset Slowly Progressive Spinocerebellar Ataxia, and Comparative Case Series with Neuropathology
Background: Genetic prion diseases, including Gerstmann‐Sträussler‐Scheinker disease (GSS), are extremely rare, fatal neurodegenerative disorders, often associated with progressive ataxia and cognitive/neuropsychiatric symptoms. GSS typically presents as a rapidly progressive cerebellar ataxia, associated with cognitive decline. Late‐onset cases are rare.Objective: To compare a novel GSS phenotype with six other cases and present pathological findings from a single case.Methods: Case series of seven GSS patients, one proceeding to autopsy.Results: Case 1 developed slowly progressive gait difficulties at age 71, mimicking a spinocerebellar ataxia, with a family history of balance problems in old age. Genome sequencing revealed a heterozygous c.392G > A (p.G131E) pathogenic variant and a c.395A > G resulting in p.129 M/V polymorphism in the PRNP gene. Probability analyses considering family history, phenotype, and a similar previously reported point mutation (p.G131V) suggest p.G131E as a new pathogenic variant. Clinical features and imaging of this case are compared with those six additional cases harboring p.P102L mutations. Autopsy findings of a case are described and were consistent with the prion pathology of GSS.Conclusions: We describe a patient with GSS with a novel p.G131E mutation in the PRNP gene, presenting with a late‐onset, slowly progressive phenotype, mimicking a spinocerebellar ataxia, and six additional cases with the typical P102L mutation.
- Open Access
- 13 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (41) , eadg3844
A cellular resolution atlas of Broca’s area
Brain cells are arranged in laminar, nuclear, or columnar structures, spanning a range of scales. Here, we construct a reliable cell census in the frontal lobe of human cerebral cortex at micrometer resolution in a magnetic resonance imaging (MRI)–referenced system using innovative imaging and analysis methodologies. MRI establishes a macroscopic reference coordinate system of laminar and cytoarchitectural boundaries. Cell counting is obtained with a digital stereological approach on the 3D reconstruction at cellular resolution from a custom-made inverted confocal light-sheet fluorescence microscope (LSFM). Mesoscale optical coherence tomography enables the registration of the distorted histological cell typing obtained with LSFM to the MRI-based atlas coordinate system. The outcome is an integrated high-resolution cellular census of Broca’s area in a human postmortem specimen, within a whole-brain reference space atlas.
- 13 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (41) , eadg3844
Open AccessA cellular resolution atlas of Broca’s area
Brain cells are arranged in laminar, nuclear, or columnar structures, spanning a range of scales. Here, we construct a reliable cell census in the frontal lobe of human cerebral cortex at micrometer resolution in a magnetic resonance imaging (MRI)–referenced system using innovative imaging and analysis methodologies. MRI establishes a macroscopic reference coordinate system of laminar and cytoarchitectural boundaries. Cell counting is obtained with a digital stereological approach on the 3D reconstruction at cellular resolution from a custom-made inverted confocal light-sheet fluorescence microscope (LSFM). Mesoscale optical coherence tomography enables the registration of the distorted histological cell typing obtained with LSFM to the MRI-based atlas coordinate system. The outcome is an integrated high-resolution cellular census of Broca’s area in a human postmortem specimen, within a whole-brain reference space atlas.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition